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Materials and methods. A retrospective study has been realized reviewing the clinical histories of 211 patients diagnosed of rectal
adenocarcinoma treated with neoadjuvant chemoradiotherapy between January 2001 and December 2010. The patients received
a dose between 45 and 50.4Gy with external radiotherapy in concomitance with chemotherapy based on ﬂuoropirimidinas.
Results. Of the 211 patients, 144 were men and 67 women, with a mean age of 62 years (30–85). Data obtained on the acute toxicity
are: cutaneous: G0: 56.8%; G1: 19.4%; G2: 15.1%; G3–4:7.1%. Genitourinary: G0: 79.6%; G1: 15.6%; G2: 3.3%; G3–4: 0%. Rectal: G0:
68.2%; G1: 20.8%; G2: 7.6%; G3–4: 2.4%. Gastrointestinal: G0: 55.9%; G1: 21.3%; G2: 14.2%; G3–4: 7.6%. Hematologic: G0: 86.2%; G1:
6.2%, G2: 2.4%, G3–4: 1.9%. 25% of patients developed late toxicity, the most frequent are intestinal obstruction and incontinence.
Relapses: 18 patients local recurrence (8.5%), 49 distant metastases (23.2%) and 12 both levels (5.7%). 15 patients had a second
tumor (7.1%). After 54 months of follow-up (3–141), overall survival was 76±5% and free survival of disease was 69±6%.
Conclusion. The results are comparable to data reported in the literature and as demonstrated in several studies, the preoperative
treatment produces a decrease of the local anddistant recurrence comparedwith postoperative treatment and survival increased.
Also, the treatment tolerance has been good and we only ﬁnd low percentage of toxicity in all grade.
http://dx.doi.org/10.1016/j.rpor.2013.03.219
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Introduction. INT-0116 study showed improvement in terms of disease free survival and overall survival using a scheme of adjuvant
chemoradiotherapy. To date, this is the standard adjuvant treatment after surgery in locally advanced gastric cancer. PURPOSE
To evaluate toxicity (RTOG scale), disease free survival (DFS), recurrence free survival (RFS) and overall survival (OS) in patients
treated with schema QT/RT in our department.
Materials and methods. Retrospective analysis of 67 patients diagnosed of gastric carcinoma and treated between October 2002
and June 2012 at “Hospital Reina Sofía” in Cordoba (Spain). Scheme of treatment: 5 cycles of chemotherapy (5-Fu/Leucovorin)
and concomitant radiotherapy (45Gy at 180 cGy/fraction) with second and third cycles. We hereby present a descriptive analysis
and survival analysis using Kaplan-Meier method. Statistic SPSS program (V10).
Results. Mean age: 61 (35–79), 75% males, 25% females. Epigastric pain was the most frequent symptom (39%) at diagnosis. Total
gastrectomy performed in 49% of patients and partial gastrectomy in 51%. The most frequent location was antrum (56.7%). Stage
distribution: IB: 4.5%, IIA: 40.3%, IIB: 9%, IIIA: 31.3%, IIIB: 9%, IV: 5%.Margins R0 in 78% andR1 in 22%. 90%of patients completed the
full treatment. Maximum toxicity recorded during concomitant treatment: Digestive G2: 28.4%, Esophagus G3: 1.5%, Leucopenia
G2: 15%, Thrombocytopenia G2: 1.5% and skin G1: 4.5%. Median follow-up was 35 months (2 - 126). OS at 3 and 5 years: 54% and
48% respectively. DFS in the same periods: 60% and 53%. 36% patients had loco-regional disease recurrence and metastases. RFS
at 3 and 5 years: 74% and 65% respectively. Median OS: 51.7% (95% CI: 12–91).
Conclusions. Chemoradiotherapy treatment for locally advanced gastric carcinoma provides good results in terms of DFS, RFS and
OS with good tolerance. Our results are similar to those described in the literature.
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Introduction. A preoperative treatment choice of rectal cancer is short-course (SC) radiotherapy (RT). In recent researches, it has
been observed that superior intervals of time to surgery seem to relate with a greater complete pathological response rate.
Objectives. Determine the existent relationship between the time until surgery with the pathological response grade (PRG). Meth-
ods: A series of 20 patients is analyzed retrospectively, collected from May/2009 until December/2012, diagnosed with rectal
adenocarcinoma (stages II and III) that received preoperative SC radiotherapy (25Gy/500 cGy session). The data was analyzed
with the statistical program SPSS v.15. The Ryan’s modiﬁed scale was used for the PRG valuation.
Results. The age rank was from 43 to 90 years (media: 76.5). 16 (80%) were of the male sex, 80% (16) correspond to T3 and 65% (13)
were N+. 7 (35%) received 1 cycle of chemotherapy pre and/or post radiotherapy and 13 (65%) radiotherapy exclusively. Regarding
to the type of surgery: Anterior resection in 10 (50%), abdominoperineal amputation in 9 (45%) and local excision in 1 (5%). The
time rank pass until surgery was from 2 to 15 weeks (median: 5 weeks). The PRG was 5 (25%), 11 (55%) and 4 (20%) for grade 1, 2
and 3 respectively. There was not grade 0. The 17% relapsed locally in the ﬁrst year. After a follow-up median of 16 months, 83%
kept free of relapses until the end of the research or until the patient decease. The local survival at 3 years was of 20%. There is
no statistical correlation between the waiting time until surgery >5 weeks and a better pathological response (p=0.57).
